Masterclass in Clinical Oncology - Summer edition

Chairs:  B.A. Jereczek-Fossa, IT – W. Wysocki, PL
Host Chair: B. Jagielska; PL

Aims, objectives and teaching format

The ESO Masterclass is a full immersion, clinical oriented event designed for medical and clinical oncologists with 3-4 years experience in oncology who would like to receive further training on the treatment of tumours from a multidisciplinary point of view. The programme exposes participants to a full spectrum of issues in clinical oncology and to practice-oriented training.
The Masterclass is organized into:

• Plenary lectures on state-of-the-art clinical treatments with reference to clinical guidelines given by renowned international faculty.
• Interactive workshops
• Clinical case presentations/tumour board simulation where each participant presents and discusses their case with an international faculty of top experts in each tumour type.

The Masterclass is divided into two educational parts:

1. Pre-recorded online lectures - from 9 May 2025
2. In-person event - 21-24 June 2025

The online lectures are released before the in-person event to give each participant the opportunity to prepare themselves in their own time and at their own pace.

The in-person event is held in the style of a 3-and-half-day ‘retreat’, giving participants the opportunity to begin building an international oncology network as well as the chance to interact with renowned faculty in an informal environment over a number of days.

The Masterclass is held entirely in English and fluency in English is necessary for admission.

The ESO Masterclass in Clinical Oncology: Summer edition is a closed event for selected participants only.

LANGUAGE

The Masterclass will be held in English and translation will not be provided.

FEE

The Masterclass will take place at the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland

A fee of:

• 300 EUR for participant working in High-Middle Income Countries *
• 200 EUR for participants working in Low-Middle income countries *

covers:

• Access to the course and its educational resources
• Accommodation for 4 nights 
• Group transfer to and from the Masterclass venue, each day of the course 
• Meals according to the programme

The fee does not cover travel costs, these should be organized and paid by the participant.

A discount of 100 EUR is given to participants who are already ESCO members.

*as defined by the World Bank

The registration fee for this event is a small contribution towards the cost for organising it, therefore it will not be refunded if a participant withdraws or is unable to attend, for whatever reason.

ACCREDITATION

Participants will be issued a certificate of attendance (minimum attendance: 75% of the online part + 100% of the in-person event). An online evaluation questionnaire and learning assessment test will need to be completed for both parts in order to get the certificate that will be sent by email.

Application for CME recognition will be submitted to the Accreditation Council of Oncology in Europe (ACOE).  

ESO College Membership

Being selected to take part in this course is one of the ESO activities that gives participants eligibility to enrol in ESO’s College. The course also enables members of the College to earn credits and therefore access more membership benefits. Full and active participation in the course earns participants 30 ESO College credits.

Visit www.ESCO.org for more information on how to join the College.

IDEAL PROFILE OF THE MASTERCLASS CANDIDATE

• Aged up to 40 years
• 2-3 years’ experience in medical oncology
• Involvement in scientific activities and clinical trials
• Fluency in English
• From ESO’s geographical reach: Europe, Mediterranean countries and Latin America

ORGANISING SECRETARIAT

Elena Fiore
European School of Oncology
ph + 39 335 169 41 60
e-mail: efiore@eso.net

Dolores Knupfer
European School of Oncology
ph +41 91 820 09 50
e-mail: dknupfer@eso.net

APPLICATION CLOSED

ATTENDANCE TO THE MASTERCLASS IS BY APPLICATION ONLY

60 PARTICIPANTS WILL BE SELECTED.

IDEAL PROFILE OF THE MASTERCLASS CANDIDATE

• Aged up to 40 years
• 2-3 years’ experience in clinical work with cancer patients
• Involvement in scientific activities and clinical trials
• Fluency in English
• From ESO’s geographical reach: Europe, Mediterranean countries and Latin America

Priority will also be given to candidates who:

• Have previously participated in ESO’s Basic Principles of Oncology course.
• Are members of ESO’s College.

HOW TO APPLY

Interested oncologists should apply online (at the top of this page).

The application process involves completing an online questionnaire, where you will provide details about:

• Your work experience and training
• Your research experience and publications
• Your motivation and personal commitment to participating in this activity

During the application, you will also need to upload the following documents in PDF format:

• Recommendation letter: A letter from your head of department or mentor, written on official hospital letterhead and signed.
• Curriculum Vitae (CV)
• Clinical case: Please use the provided template available below.

SELECTION PROCESS

Applications are evaluated through a two-step process:

1. Automated Scoring: Some responses are assessed using a predefined scoring system to ensure fairness and consistency. Points are assigned based on your answers.
2. Committee Evaluation: Other sections, including your qualitative responses, are reviewed and scored by our selection committee.

This type of evaluation ensures a transparent and unbiased selection of top candidates for participation in this activity.

Before you start completing the online application form, please be sure you have all the requested files (CV, Recommendation letter, and Clinical Case template) ready to be uploaded to the system. Online applications will not be considered unless all the files are uploaded.

TEMPLATES

• Download your Clinical case template HERE

CLINICAL CASE PRESENTATION

During the in-person event all participants will have the chance to present a clinical case as a clinical grandround discussion to the faculty and participants.

A template giving details of the clinical case you would like to present should be submitted with your application. Please provide a straightforward case found in your daily clinical practice - no uncommon or extremely rare cases. You should include

• Diagnostic considerations
• Treatment
• Results, follow-up
• At least three questions proposed for discussion with the faculty

If you are selected for the Masterclass, you will be asked to prepare a PowerPoint presentation of your case (max 10 slides). If we receive too many cases from one tumour group, we may ask you to change the case topic you submitted during your application. We kindly ask you to let us know your 2^nd choice topic if your first choice cannot be accommodated.

Dirk Arnold, Asklepios Tumorzentrum Hamburg, Dept. of Oncology, Hematology and Palliative Care, Hamburg, DE
Riccardo A. Audisio, Institute of Clinical Sciences - Sahlgrenska University Hospital, Dept. of Surgery, Göteborg, SE
Riccardo A. Audisio, Institute of Clinical Sciences - Sahlgrenska University Hospital, Dept. of Surgery, Göteborg, SE
Giulia Baciarello, San Camillo-Forlanini Hospitals, Medical Oncology Dpt., Rome, IT
Luca Bertolaccini, IEO, Istituto Europeo di Oncologia IRCCS, Thoracic Surgery Dpt., Milano, IT
Joerg Beyer, University Hospital of Bern, Oncology and Medicine Dept., Bern, CH
Justyna Bochenek-Cibor, St' Lukas Hospital, Radiation Therapy Dpt., Tarnów, PL
Lubomir Bodnar, Sp Zoz Mswia, Clinical Oncology Dept., Olsztyn, PL
Antonio Calles, University General Hospital Gregorio Maranon, Dept. of Thoracic Oncology, Madrid, ES
Felipe A. Calvo Manuel, Clinica Universidad de Navarra, Dept. of Radiation Oncology, Madrid, ES
Fatima Cardoso, Champalimaud Clinical Center, Breast Unit, Lisbon, PT
Paolo Giovanni Casali, National Cancer Institute - IRCCS Foundation, Medical Oncology Unit 2, Milan, IT
Paolo Giovanni Casali, National Cancer Institute - IRCCS Foundation, Medical Oncology Unit 2, Milan, IT
Franco Cavalli, Foundation for the Institute of Oncology Research (IOR), Presidenza, Bellinzona, CH
Nicoletta Colombo, Istituto Europeo di Oncologia, Programma Ginecologia Oncologica, Milano, IT
Carmen Criscitiello, European Institute of Oncology, New Drugs and Early Drug Development for Innovative Therapies Dpt., Milan, IT
Giuseppe Curigliano, European Institute of Oncology / University of Milan, New Drugs for Innovative Therapies Division, Milano, IT
Alessandra Curioni-Fontecedro, Freiburger Spital, HFR Kantonsspital Freiburg, Department of Oncology, Freiburg, CH
Sara De Dosso, Oncology Institute of Southern Switzerland (IOSI), Medical Oncology Dpt., Bellinzona, CH
Francesca Del Bufalo, IRCCS Peadiatric Hospital Bambino Gesù, Cellular and Genic Therapy Dpt., Roma, IT
Andre D'Hoore, UZ Gasthuisberg, Dept. of Surgery, Leuven, BE
Antonio Di Meglio, Gustave Roussy Institute, Medical Oncology Dpt., Villejuif, FR
Andreas Dietz, University Hospital Leipzig, ENT Dpt., Leipzig, DE
Michel Ducreux, Institute Gustave Roussy, Oncology, Villejuif, FR
Rafal Dziadziuszko, Medical University of Gdansk, Oncology and Radiotherapy Dpt., Gdansk, PL
Alexandru Eniu, Riviera-Chablais Hospital, Medical Oncology Dpt., Rennaz, CH
Andrea Ferrari, Fondazione IRCCS Istituto Nazionale dei Tumori, Div. di Oncologia Pediatrica, Milano, IT
Tania Fleitas Kanonnikoff, Hospital Clinico Universitario de Valencia, Clinical Oncology Dpt., Valencia, ES
Andrea Gallina, EOC - Ente Ospedaliero Cantonale, Urology Dpt., Bellinzona, CH
Angelika Gawlik-Urban, Maria Sklodowska-curie National Research Institute Of Oncology (mscnrio)., Gynecological Oncology Clinic, Crakow, PL
Fady B. Geara, Cleveland Clinic Abu Dhabi, Dept. of Radiation Oncology, Abu Dhabi, AE
Patrizia Giannatempo, Fondazione IRCCS Istituto Tumori, Medical Oncology Dpt., Milano, IT
Juan Francisco Grau Bejar, Vall d´Hebron University Hospital, Gynaecological Cancer Dpt., Barcelona, ES
Alessandro Gronchi, National Cancer Institute - IRCCS Foundation, Sarcomas Surgery Unit, Milano, IT
Milos Grujic, University Clinical Center Kragujevac, Radiation Oncology Dept., Kragujevac, RS
Beata Jagielska, Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy, Narodowy Instytut Onkologii, Warsaw, PL
Barbara Alicja Jereczek-Fossa, European Institute of Oncology, Dept. of Radiotherapy, Milano, IT
Dragana Jovanovic, Belgrade, RS
Johannes Knoth, Comprehensive Cancer Center, Dept. of Radiation Oncology, Wien, AT
Hanna Kosela, Memorial Cancer Center and Institute of Oncology, Department of Soft Tissue/Bone Sarcoma and Melanoma, Warsaw, PL
Jaroslaw Kuzdzal, Krakow, PL
Angela Lamarca, Fundación Jiménez Díaz University Hospital, Department of Oncology – OncoHealth Institute, Madrid, ES
Pauline Leonard, National Health Service, Oncology and Communication Dpt., London, UK
Umberto Malapelle, University of Naples Federico II, Dpt. of Public Health, Naples, IT
Olivier Michielin, Geneve University Hospital, Medical Oncology Dpt., Geneve, CH
Ernest Nadal, Institut Català  d'Oncologia, Medical Oncology Department, L'Hospitalet (Barcelona), ES
Jarushka Naidoo, Waterford Regional Hospital, Medical Oncology Dpt., Waterford, IE
Demetris Papamichael, Bank of Cyprus Oncology Centre, Medical Oncology Dpt., Nicosia, CY
Anes Pasic, University Clinical Center Maribor (UKC Maribor), Oncology Dept., Maribor, SI
Anes Pasic, University Clinical Center Maribor (UKC Maribor), Oncology Dept., Maribor, SI
Philip Poortmans, Iridium Netwerk & University of Antwerp, Dept. of Radiation Oncology, Wilrijk, BE
Eleonora Petra Preti, IEO - European Institute of Oncology, Gynaecological Cancer Dpt., Milan, IT
Giancarlo Pruneri, National Cancer Institute, IRCCS Foundation, Pathology Dpt., Milano, IT
Amanda Psyrri, Attikon University Hospital, Medical Oncology Dept., Chaidari, GR
Miroslawa Puskulluoglu, Maria Sklodowska-Curie National Research Institute of Oncology, Kraków Branch, Dept. of Clinical Oncology, Krakow, PL
Sara Ramella, University Campus Bio-Medico, Radiotherapy Dpt., Roma, IT
Isabelle Ray-Coquard, Léon Bérard Center, Dept. of Medical Oncology, Lyon, FR
Alberto Righi, Istituto Ortopedico Rizzoli, Dip. di Patologia, Bologna, IT
Lorenza Rimassa, IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Pieve Emanuele (Milan), IT
Christian Rolfo, The Arthur G. James Comprehensive Cancer Center, Division of Medical Oncology, Columbus, OH, US
Piotr Rutkowski, Maria Sklodowska-Curie National Research Institute of Oncology, Dept. of Soft Tissue/Bone & Melanoma, Warszawa, PL
Marzia Salgarello, Policlinico Gemelli, Recostructive Surgery Dpt., Rome, IT
Andrea Sartore-Bianchi, Niguarda Hospital, Division of Clinical Research and Innovation, Milano, IT
Manuela Schmidinger, Medical University of Vienna, Department of Urology and Comprehensive Cancer Center, Vienna, AT
Joachim Schuz, AIRC - International Agency for Research on Cancer, Environment and Lifestyle Epidemiology Branch, Lyon, FR
Elzbieta Senkus, Medical University of Gdansk, Dept. of Oncology and Radiotherapy, Gdansk, PL
Cristiana Sessa, Istituto Oncologico della Svizzera Italiana, Gynaecology Dpt., Bellinzona, CH
Cristiana Sessa, Istituto Oncologico della Svizzera Italiana, Gynaecology Dpt., Bellinzona, CH
Thomas Seufferlein, Ulm University Hospital, Dept. of Internal Medicine I, Ulm, DE
Alexander Siebenhüner, Kantonsspital Schaffhausen, Oncology Dpt., Schaffhausen, CH
Iwona Skoneczna, M. Sklodowska-Curie Memorial, Oncology Dept., Warsaw, PL
Mateusz Spalek, Maria Sklodowska-Curie Institute - Cancer Center, Soft Tissue/Bone Sarcoma and Melanoma Dpt., Warsaw, PL
Antoni Szczepanik, Uniwersytet Jagiellonski – Collegium Medicum, ., Krakow, PL
Anna Szumera-cieckiewicz, Maria Sklodowska-curie Cancer Institute, Biobank, Warsaw, PL
Ian Tannock, Toronto, CA
Ian Tannock, Toronto, CA
Annalisa Trama, National Cancer Institute - IRCCS Foundation, ., Milano, IT
Eric Van Cutsem, University Hospital Leuven, Digestive Oncology Dept., Leuven, BE
Bruno Vincenzi, University Campus Bio-Medico, Medical Oncology Dpt., Rome, IT
Marco Vitellaro, Fondazione IRCCS Istituto Nazionale dei Tumori, Surgical Oncology Dpt., Milano, IT
Ursula Vogl, Cantonal Hospital of Southern Switzerland (EOC), IOSI - Oncology Institute of Southern Switzerland, Bellinzona, CH
Lucjan Wyrwicz, Maria Sklodowska-Curie National Cancer Research Institute, Dept. of Oncology and Radiotherapy, Warsaw, PL
Wojciech Wysocki, Maria Sklodowska-Curie Memorial Institute Of Oncology, Scientific Editorial Office, Warsaw, PL
Mycola Zubaryev, National Cancer Institute of Ukraine, Kyiv, UA